Appeal No. 1997-2167
Application 08/137,444
inhibit AChE; and, a second where memory dysfunction
characterized by decreased cholinergic function is treated
with 6-O-demethylgalanthamine, a known AChE inhibiting
compound, by administering to a mammal in an amount sufficient
to inhibit AChE the compound of Claim 2 where R is hydrogen.3
Thus, both methods are limited to treating memory dysfunction
characterized by decreased cholinergic function.
The first method requires administering to a mammal with
memory dysfunction characterized by decreased cholinergic
function an amount of the compound of claim 1 sufficient to
inhibit the formation in the mammal of the enzyme AchE. As a
"comprising" claim the first method does not exclude any other
step or ingredient, including steps or ingredients disclosed
but not claimed and even steps or ingredients neither
disclosed or even contemplated. The second method requires
administering to a mammal with memory dysfunction
characterized by decreased cholinergic function the compound
6-O-demethylgalanthamine by administering to said mammal in an
amount sufficient to inhibit the formation in the mammal of
AChE the compound of Claim 2 or 31 which metabolizes to 6-O-
demethylgalanthamine. Like the first method, the second
method is open to other steps and ingredients, both disclosed
8
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007